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Abstract 
Background: The Italian Clinical network for FSHD (ICNF) has established the Italian National Registry for FSHD (INRF), 
collecting data from patients affected by Facioscapulohumeral dystrophy (FSHD) and their relatives. The INRF has 
gathered data from molecular analysis, clinical evaluation, anamnestic information, and family history from more than 
3500 participants.
Methods: A data management framework, called Mediator Environment for Multiple Information Sources (MOMIS) 
FSHD Web Platform, has been developed to provide charts, maps and search tools customized for specific needs. 
Patients’ samples and their clinical information derives from the Italian Clinical network for FSHD (ICNF), a consortium 
consisting of fourteen neuromuscular clinics distributed across Italy. The tools used to collect, integrate, and visualize 
clinical, molecular and natural history information about patients affected by FSHD and their relatives are described.
Results: The INRF collected the molecular data regarding FSHD diagnosis conducted on 7197 subjects and identified 
3362 individuals carrying a D4Z4 Reduced Allele (DRA): 1634 were unrelated index cases. In 1032 cases the molecular 
testing has been extended to 3747 relatives, 1728 carrying a DRA. Since 2009 molecular analysis has been accom-
panied by clinical evaluation based standardized evaluation protocols. In the period 2009–2020, 3577 clinical forms 
have been collected, 2059 follow the Comprehensive Clinical Evaluation form (CCEF). The integration of standardized 
clinical information and molecular data has made possible to demonstrate the wide phenotypic variability of FSHD. 
The MOMIS (Mediator Environment for Multiple Information Sources) data integration framework allowed perform-
ing genotype–phenotype correlation studies, and generated information of medical importance either for clinical 
practice or genetic counseling.
Conclusion: The platform implemented for the FSHD Registry data collection based on OpenClinica meets the 
requirement to integrate patient/disease information, as well as the need to adapt dynamically to security and privacy 
concerns. Our results indicate that the quality of data collection in a multi-integrated approach is fundamental for 
clinical and epidemiological research in a rare disease and may have great value in allowing us to redefine diagnos-
tic criteria and disease markers for FSHD. By extending the use of the MOMIS data integration framework to other 
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) 
(MIM#158900), the third most common hereditary myo-
pathy with prevalence of 1 in 20,000 [1], is characterized 
by progressive and variable atrophy and weakness of the 
facial, shoulder, and upper-arm muscles [2]. Wide vari-
ability of the clinical spectrum ranging from asympto-
matic subjects to patients who are wheelchair dependent 
has been described among and within FSHD families [3]. 
Before the advent of molecular diagnosis, penetrance of 
FSHD was evaluated on clinical examination of patients 
at risk and estimated between 83 and 95% by the age of 
20  years [4]. FSHD is considered an autosomal domi-
nant disorder, associated with rearrangements occur-
ring in a 3.3 kilobase (kb) tandemly repeated sequence 
(D4Z4) located at the 4q subtelomere [5]. The analysis of 
FSHD penetrance [3, 6–14] reinforced the idea that addi-
tional elements take part in disease onset and progres-
sion. Indeed, the clinical variability and non-penetrance 
observed in presence of the same molecular defect affect 
diagnosis, prognosis, genetic counseling. Besides having 
a great impact in clinical practice, the observed pheno-
typic heterogeneity is also affecting research and readi-
ness to clinical trials. To address these issues, the Italian 
Clinical Network for FSHD (ICNF) developed clinical 
tools, the FSHD scale (that computes the FSHD score 
[15], and the Comprehensive Clinical Evaluation Form 
(CCEF) [16], for the standardized evaluation of subjects. 
Based on the observed phenotypic features, one indi-
vidual can be assigned to one of four different pheno-
typic categories (A, B, C, D). To integrate molecular data 
with clinical data the Italian National Consortium for 
FSHD (INCF) established the Italian National Registry 
for FSHD (INRF). The INRF has accrued 3362 subjects 
carrying D4Z4 Reduced Alleles (DRA), including 1032 
unrelated families with 1728 relatives heterozygotes for 
a DRA. This large collection of data, the largest world-
wide, has enormous potential for providing clinical and 
epidemiological information and requires suitable tools 
for proper collection, storage and analysis.
In 2016, a collaboration between the INCF and Data-
River S.r.l. realized the MOMIS FSHD Web Platform. It 
consists of two main web modules, based on the open-
source EDC platform OpenClinica and the MOMIS Data 
Integration System for data search, analysis, and extrac-
tion. The integration of multiple distributed data sources 
with genomic information, family origin and instrumen-
tal investigations will result in a greater depth and fast 
growth of information that will be managed. The MOMIS 
FSHD Web Platform is an open framework to enable col-
laboration and knowledge exchange for biomedical and 
clinical research. All information from different sources 
is integrated to constitute a solid support for clinical 
practice and research on the disease.
Here we describe the organization and summarize the 




The MOMIS FSHD Web Platform integrates data com-
ing from different, heterogeneous and fragmented data 
sources. The platform provides a unified vision of inte-
grated clinical data to facilitate data exploration and ana-
lytics through the MOMIS data integration system.
Figure 1 shows the architecture of the FSHD Registry. 
Integrated data came from three different sources:
• Family Pedigree Charts reporting the family pedigree 
of each index case;
• Molecular DB web platform contains molecular anal-
ysis data of patients and their relatives;
• Clinical DB web platform contains clinical data of 
patients and their relatives.
For the integration of these three data sources, we used 
the MOMIS (Mediator Environment for Multiple Infor-
mation Sources) data integration framework designed 
by the DBGROUP at the University of Modena & Reg-
gio Emilia and developed by DataRiver. MOMIS builds 
a virtual unified schema, which preserves the independ-
ence and security of original data sources allowing users 
to formulate queries on it. The integration process con-
sists of four main steps: (i) connection sources and auto-
matic extraction of schema of the selected data sources; 
(ii) automatic annotation of the schemas attributes, i.e., 
one or more meanings is associated to each of them; (iii) 
attributes with the same meanings are automatically con-
nected by semantic mappings; (iv) finally, a global schema 
is generated and can be manually refined by the data inte-
grator designer.
countries and the longitudinal systematic collection of standardized clinical data will facilitate the understanding of 
disease natural history and offer valuable inputs towards trial readiness. This approach is of high significance to FSHD 
medical community and also to rare disease research in general.
Keywords: Rare disease registry, Data collection, Data integration, FSHD, Rare diseases
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MOMIS has already been used in several integration 
projects [17], including clinical trials and public authori-
ties data management [18]. The MOMIS FSHD Web Plat-
form relies on OpenClinica™ Community Edition (Fig. 1) 
to manage Clinical Data information, strengthening data 
quality and efficiency. The data collected through Open-
Clinica are displayed through the MOMIS Dashboard 
[17, 18]: a MOMIS framework’s web tool for data analysis 
and monitoring tool realized by DataRiver (Fig. 1).
OpenClinica database
The INRF Database collects clinical and molecular data 
from both index cases and their relatives.
To manage an auditable collection of clinical data we 
used the open-source web application OpenClinica™ 
Community Edition. The OpenClinica Electronic Data 
Capture (EDC) system is a widely used and well-trusted 
clinical research web platform used for all types of clini-
cal studies, population and rare disease registries. It 
is currently used by hundreds of research centers and 
institutions in over 100 countries and can rely on a com-
munity of about 18,000 users. The platform is compli-
ant with NIH, HIPAA, 21 CFR Part 11 requirements and 
regulatory guidelines for clinical data management [19]. 
OpenClinica is designed as a standards-based, extensi-
ble, and modular platform, to guarantee the absolute and 
strict compliance with the confidentiality and security 
constraints of access to highly sensitive data.
The OpenClinica platform has been extended with the 
EDC module to provide the user with specific features to 
manage sample providers, families, probands and pedi-
grees. Blood relationships between subjects are crucial to 
study in detail the families and sporadic cases in which 
there is an identified molecular defect typical of FSHD. 
The customized software modules allow users to man-
age family relationships, identifying the proband (the 
first family subject affected by disease) and streamlin-
ing searches on family branches that could be far from 
their geographical origin. Through a secure connection, 
the EDC module allows users to easily switch between 
the MOMIS Dashboard search and monitoring tool; the 
custom software modules to manage families, probands 
and subjects; the data capture forms implemented on 
OpenClinica.
MOMIS data processing workflow
When the sample of a new patient arrives at the Miogen 
Lab, the MOMIS FSHD Web Platform provides a new 
and unique identifier in the format ID/YEAR. The system 
then creates two new Events in OpenClinica: “Registra-
tion” and “Visit”. The Registration form is designed to col-
lect the participant’s personal data and other information 
concerning the arrival day of the sample, the National 
Health System request, and the informed consent. The 
visit event includes the Molecular and the Comprehensive 
Clinical Evaluation Form (CCEF) modules. Case Report 
Forms (CRFs) are designed to accurately collect all this 
Fig. 1 Architecture of the INRF based on the MOMIS FSHD Web Platform
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information from each subject investigated by the ICNF. 
This allows performing a solid epidemiologic data analy-
sis based on the study of families and sporadic cases.
The modularity, the flexibility, and the ability to create 
custom forms and fields made the platform a very suit-
able resource to accomplish our purposes.
The MOMIS Dashboard in the clinical practice of FSHD
1. The molecular module
The Molecular module is used for tracking the sample 
in each step of molecular analyses (e.g., the identifiers 
of the autoradiographs showing the results of molecu-
lar investigation, or the sample storage location). As the 
final step of the molecular analysis, the allelic profile of 
the patient is reported. The molecular report contains 
the size of each D4Z4 allele at specific loci (i.e., Chr-4 
q35 or Chr-10 q26), alleles of the qA/qB polymorphism. 
Additional molecular information such as the presence 
of a polyadenylation signal (PAS) and/or simple sequence 
length polymorphism (SSLP) or D4Z4 methylation sta-
tus can be uploaded. It is also possible to register addi-
tional molecular information such as Next Generation 
Sequencing data.
2. The comprehensive clinical evaluation form
Medical experience and systematic clinical evaluation 
of hundreds of participants guided the evolution of the 
clinical form from the original FSHD Clinical Form [15], 
to the Comprehensive Clinical Evaluation Form (CCEF) 
[16], which collects several additional information such 
as comorbidities, common and uncommon signs of the 
disease, lifestyle habits, and more importantly the clini-
cal categories. The CCEF has been validated and frozen 
in 2016 [16]. The CCEF is organized in four sections as 
summarized in Table 1.
The FSHD Evaluation Scale is used to calculate the 
FSHD clinical score based on the regional distribution of 
muscle weakness and the functionality of muscle groups. 
The FSHD score ranges from 0 to 15 and indicates the 
severity of the motor impairment.
The Clinical Diagnostic section is used to report the 
combination of typical or uncommon clinical features of 
FSHD.
The section  4, Clinical Categories, assigns the indi-
vidual to one out of four different phenotypic categories: 
typical FSHD (category A, subcategories A1, A2, A3), 
incomplete phenotypes (category B, subcategories B1, 
B2), asymptomatic/healthy subjects (category C, subcat-
egories C1, C2) and atypical/complex phenotypes (cat-
egory D, subcategories D1, D2).
The development of the Molecular report and the 
CCEF in OpenClinica has generated unprecedented 
possibilities towards the understanding of the FSHD 
disease. The collection and management of numeric 
and objective data regarding patients and families 
makes the search for patterns and correlations not only 
feasible but also easy.
3. The filtering module
In clinical practice, the MOMIS FSHD Web Platform 
can be used to obtain an integrated view of data coming 
from several commercial DBMSs. The graphical inter-
face of MOMIS Dashboard allows a quick and effective 
data extraction from the database. Since 2007, the Ital-
ian Registry for FSHD has collected clinical data com-
ing from 3577 subjects (3362 DRA carriers). For a first 
cursory analysis subjects can be grouped, classified, 
and filtered for one or more features. For this reason, 
the MOMIS FSHD Web Platform’s homepage provides 
different features to filter the overall database popula-
tion and to extract valuable information in the Micro-
soft Excel Spreadsheet format.
The filter options include:
1. Subject: this option filters by subject ID, name, sur-
name, restricting the search to only ‘probands’ (index 
cases of unrelated families). It is also possible to 
select only subjects who received a FSHD Score (an 
index of degree of muscle impairment), within a con-
figurable range.
2. Category: it is possible to filter by the phenotypic 
clinical category. On the basis of the observed pheno-
typic features, one individual can be assigned to one 
out of four different phenotypic clinical categories: 
typical FSHD (category A, subcategories A1, A2, A3), 
incomplete phenotypes (category B, subcategories 
B1, B2), asymptomatic/healthy subjects (category C, 
subcategories C1, C2) and atypical/complex pheno-
types (category D, subcategories D1, D2) [15].
3. Family: filters by family name.
4. Registration Year: the year of patient registration in 
the database can be selected.
5. Alleles: filters by the characteristics of the monitored 
alleles, e.g., encountered peculiarities, type of trans-
location and allele size.
The MOMIS FSHD Web Platform shows other dif-
ferent tabs, clustering patients for other features, 
including:
1. The number of subjects registered every year as well 
as the enrollment trend is a metric that is useful for 
planning resources and procurement.
2. Subjects enrolled by location, showing on a map the 
geographic distribution of the patients.
3. The distribution of alleles within subjects accrued by 
the INRF, on the basis of their size, for a specific phe-
notypic category.
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All these filtering options can be combined for a finer 
level of analysis and the MOMIS FSHD Web Platform 
could then generate graphs allowing an overview of data.
4. Principle of data governance
The INRF complies with practices indicated for the 
good governance of a registry. The team has different and 
complementary expertise, including a named registry 
lead, a statistician, data stewardship and database man-
agement, development and hosting and a legal specialist. 
Each clinical center, headed by a designated candidate, 
has the responsibility to train their medical staff about 
the clinical procedures adopted by the registry. Once per 
year, a round table discussion is planned in order to chew 
over the concerns of the group and define key objectives.
With regard to privacy policies, INRF adheres to “EU 
General Data Protection Regulation (GDPR)”.
5. Data access
Data management is performed by DataRiver srl, which 
exercises the utmost care to ensure that all the confiden-
tial information stays protected from prying access.
Data is collected according to the principles of lawful-
ness, fairness and transparency, carefully applying spe-
cific Standard Operation Procedures (SOP) in order to 
prevent and detect any exposure of personal and sensi-
tive data and adopt proper risk mitigation measures.
DataRiver follows all the best practices and the laws to 
ensure the protection of the personal data of the patients, 
all the system is compliant with EU General Data Protec-
tion Regulation (GDPR).
Data is stored on a dedicated server hosted by a UNI 
EN ISO 27001:2005 certified server farm to ensure the 
physical, logical and organizational security of informa-
tion. The server is protected by firewall configurations 
and remote access is allowed only to the authorized sys-
tem administrator through SSH connection with authen-
tication via asymmetric key pair.
Sensitive data are stored in a database implementing 
encryption at the filesystem level, in compliance with 
the requirements of the GDPR (art.32) and with the pub-
lished guidelines by the European Union Agency for Net-
work and Information Security (ENISA—Manual on the 
Security of Personal Data Processing).
Data that necessary allow the identification of the sub-
jects for research and patient’s care purposes are stored 
in a separate database and made available to authorized 
users on a role-based permission system implemented by 
the registry platform in order to guarantee the minimiza-
tion of the access to personal data.
The access to patients’ personal information is author-
ized exclusively for staff working at Miogen lab, with the 
consensus of the curator of the Registry. Every mem-
ber of the staff has personal credentials for accessing 
Momis platform and in agreement with the curator of the 
Registry have the permission to manage the data (inser-
tion, corrections, extraction, quality control). The agree-
ment between the curator of the Registry and the staff is 
to maintain the confidentiality of all the information col-
lected. When the employment relationship is over, the 
access for the member of the staff is immediately inter-
rupted. If requested, anonymized data are provided to 
collaborators for cohort studies.
6. Data ownership
The principal investigator of the INFR is the curator of 
the data and acts as the “data controller” of the registries 
and assumes all the responsibility for the protection of 
the data, its storage, use and access. When processed, the 
data become research data and are then the intellectual 
property of the investigator who is the “third party”.
7. Data management
DataRiver provides remote help-desk service and sup-
port to the users of the platform on weekdays during 
working hours, as established by contract. The helpdesk 
and support service includes the creation and manage-
ment of user accounts, the solution of problems related 
to the ordinary platform usage and maintenance, the 
analysis, application and documentation of any extraor-
dinary interventions to address issues related to the 
process of entry, edit and management of the registry’s 
clinical data. The INRF is operating to reach high-quality 
data level, and interoperability based on FAIR principles 
(i.e., Findable, Accessible, Interoperable and Reusable) in 
order to make data available for wider use.
Results
Data collection and management model for a rare disease
The MOMIS FSHD Web Platform is the Italian national 
data repository for FSHD and represents a fundamental 
tool for collecting and managing anamnestic, clinical, 
and molecular data of all Italian subjects accrued through 
the INRF. Biological samples of participants and their 
clinical information were collected by the ICNF, which 
consists of 14 centers specialized in neuromuscular dis-
eases located across Italy and a centralized laboratory, the 
Miogen lab, dedicated to molecular analyses for FSHD 
(Fig. 2). The Miogen lab has been a reference center for 
the molecular diagnosis of FSHD which has been con-
ducted on 7197 subjects. 3362 individuals carry a DRA: 
1634 probands unrelated to each other, of these 602 are 
isolated cases (with no other family members investi-
gated). In 1032 cases, molecular investigation has been 
extended to other family members. Of 3747 molecularly 
tested relatives, 1728 were heterozygotes for a DRA.
Thanks to the analysis of 3577 clinical forms collected 
since 2009, it has been possible to establish that 2165 
participants (60.5%) had muscle impairment with dif-
ferent degree of severity, from mild (FSHD score 1–2) 
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to moderate (FSHD score 3–7) and severe (FSHD score 
8–15). In the period 2015–2019, 2059 subjects were eval-
uated following the CCEF, which led to a more precise 
phenotypic description. Through the CCEF it was pos-
sible to demonstrate that the wide phenotypic variability 
of participants: (55.4%) present a myopathic phenotype 
compatible with FSHD (Clinical Categories A, B and D1) 
and 134 (6.5%) presented muscle impairment that was 
not compatible with FSHD diagnosis. Since the establish-
ment of the INRF in 2007, the number of enrolled sub-
jects has been steadily increasing until 2015, the time the 
CCEF has been applied for the clinical evaluation (Addi-
tional file  1A). From 2015, the enrollment of subjects 
with a myopathic FSHD-like phenotype (categories A, B, 
and D) has been steady (Additional File 1B). Since FSHD 
prevalence is 1 in 20,000 [1] with an estimate of 3,030 
people affected by FSHD in Italy, indicate that the col-
lection of subjects accrued by the INRF might be largely 
representative of the Italian population. As a result, this 
centralized data collection offers the possibility of con-
ducting clinical and epidemiological studies with high 
statistical power.
The MOMIS FSHD web platform application in clinical 
research
The most relevant feature of the MOMIS FSHD Web 
Platform is the population-based systematic collection 
of clinical and anamnestic data. This has fostered clini-
cal and epidemiological research in a rare disease such as 
FSHD. It is now clear that clinical variability is a relevant 
part of hereditary diseases and that the disease expres-
sion and evolution is determined by several factors. 
In the case of FSHD this aspect is of great importance 
especially because the molecular marker used for FSHD 
diagnosis is a common polymorphism [20]. Assuming 
that the presence of DRA constitutes a susceptibility 
Fig. 2 The ICNF-INRF-MOMIS FSHD Web Platform interaction network. Subjects are recruited by the ICNF, a consortium consisting of 14 centers 
specialized in neuromuscular diseases located across Italy. Biological samples of participants and their clinical information are collected in Modena 
for molecular analysis and database integration in INRF. MOMIS FSHD Web Platform filtering options allow patients selection for clinical and research 
purposes
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factor there might be several elements contributing to 
disease expression. In particular, the genotype–pheno-
type correlation on the basis of the MOMIS FSHD Web 
Platform’s database has generated information of medi-
cal importance either for clinical practice or for genetic 
counseling (Table 2). Based on our earlier consideration, 
it clearly appears that one of the most important usages 
of the MOMIS FSHD Web Platform is represented by 
its filtering options that allows clustering subjects based 
on specific characteristics. The selection of cohorts of 
subjects for epidemiological studies aimed at addressing 
specific questions is based on the MOMIS interrogation, 
which strongly shortens the time for the subject’s collec-
tion and minimizes errors. Patients are selected based 
on the information reported in the database, including 
anamnestic information. Selection can be very specific: 
for example, it is possible to select people from a certain 
region, carrying DRA with 4–8 repeat units, who prac-
ticed sports; or we may filter for females, category A, 
with at least one pregnancy belonging to a family with 
other relatives affected. Another valuable aspect of the 
MOMIS FSHD Web Platform is the ability to carry out 
family studies, defining in each family the characteris-
tics of the proband and relatives. As shown in Table  1, 
the platform has been successfully applied to many dif-
ferent aspects of FSHD research: 1) the CCEF validation 
[16] 2) the genotype/phenotype characterization of peo-
ple carrying specific molecular features: 1–3 DRA [14] or 
7–8 DRA [21] or 9–10 [22] 3) follow up studies [23]. The 
MOMIS FSHD Web Platform has also been used 4) for 
molecular research on D4Z4 epigenetic regulation [24] or 
5) to identify genetic interactions with other rare diseases 
[25].
INRF in the scheme of the world
Several entities for patients’ data collection have been 
established in the last years including national, European 
and global Rare Diseases (RDs) registries responding to 
the rising requests from patient organizations, regulatory 
agencies and healthcare professionals for curated data 
serving epidemiological and clinical research on RDs.
At the European level, several platforms have been 
create: the European Platform for rare disease registries 
(EPIRARE: www. epira re. eu), the International Rare Dis-
ease Research Consortium, (IRDiRC: www. irdirc. org) 
and the Integrated Platform connecting databases, reg-
istries, biobanks and clinical bioinformatics for Rare 
Disease research (RD-Connect: www. rd- conne ct. eu). In 
February 2017, 24 European Reference Networks (ERNs) 
(https:// www. ern- rnd. eu) were established in a European 
legal framework, of which 23 are dedicated to rare or 
low prevalence complex diseases or conditions. An Ital-
ian national institutional registry of rare disease patients, 
the Registro Nazionale Malattie Rare (RNMR), has been 
established in Italy in 2001 by the National Centre for 
Rare Diseases (Centro Nazionale Malattie Rare, CNMR) 
of the Istituto Superiore di Sanità (National Institute of 
Health) [26]. The registry is not exhaustive of all RDs and 
FSHD is underrepresented as well as other Neuromus-
cular disorders (NMD) as this database comprises RDs 
characterized by congenital syndromes, severe clinical 
conditions, high level of invalidity, and costly treatments. 
Here, diseases of the musculoskeletal system and connec-
tive tissue are globally the 5.5% of total records.
Neuromuscular diseases specific registries are present 
worldwide and globally described within the TREAT-
NMD neuromuscular network website (https:// treat- 
nmd. org/ patie nt- regis tries). The TREAT-NMD network 
has developed a specific tool, the TREAT-NMD Global 
Registry Network, where registries are listed regard-
ing the principal NMD disorders worldwide, including 
FSHD. Recently, a collaboration between TREAT-NMD 
and ERNs was launched, leading to the establishment of 
a “FSHD European Trial Network”. The INRF is part of 
this network.
According to data provided by the FSH Society, we 
were able to compare a total of 23 FSHD registries 
located in 5 continents (4 in Asia, 1 in Africa, 4 in Amer-
ica, 11 in Europe and 3 in Oceania) [27–32] which were 
collectively analyzed based on patient’s number within 
and on specific features as reported in Fig.  3 and in 
Additional file 2. In particular, Fig. 3 shows the number 
of FSHD subjects present in each platform as the per-
centage value over the total number of patients accrued 
by all registries. Notably, the pie chart highlights that 
the INFR alone accounts for 26% of total FSHD patients 
worldwide. Given the reported values, we selected regis-
tries including a significant number of patients, at least 
5% of total number, for further consideration. Additional 
file  2 shows demographic, clinical/molecular and logis-
tics parameters. We also evaluated the ratio between the 
number of accrued FSHD subjects over the total country 
population. This parameter varies among countries and 
may be useful to estimate the ‘recruitment power’ of sin-
gle registries. Additional file 2 also shows that the INFR 
platform is unique among the various FSHD registries, as 
clinical and anamnestic information are totally reported 
by the ICNF-clinicians through the CCEF template and 
all accrued subjects are molecularly investigated.
Discussion
The expanding use of DNA molecular analysis applied 
to diseases with a genetic basis has revealed increasingly 
varied phenotypic spectra in patients carrying muta-
tions in the same gene, as one can see by the number of 
reviews [3, 33, 34].
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It is now clear that the well-phenotyped and geneti-
cally characterized patient cohorts can promote a more 
accurate treatment of patients. These steps are neces-
sary to develop appropriate outcome measures and bio-
markers and to proceed towards trial readiness. The 
limited knowledge about the natural history of RDs, 
their chronicity, need for long-term follow-up and high 
demand for assistance represent a special challenge for 
the healthcare systems. The management of all these 
needs and questions requires a large amount of informa-
tion to be collected. In this respect RD or disease-specific 
data collection hubs with the possibility of integrating 
data available in different locations and the manage-
ment of continuously increasing information related to 
a single sample are key instruments for the surveillance 
of these diseases, with the aim of improving patients 
and caregivers quality of life and for therapeutic plan-
ning. Thus, the term "Registry" has now gone beyond the 
original significance of a collection of mere anagraphic/
demographic data. The great effort is directed towards 
combining genomic, anamnestic and clinical investiga-
tion. This important process requires a solid description 
of clinical data and appropriate Big Data techniques to 
exploit the potential of the wealth of information that 
can be acquired. In the case of FSHD, the MOMIS FSHD 
Web Platform serves these purposes. The collection of 
participants evaluated with a standardized methodol-
ogy with demonstrated interrater reliability is the major 
strength of the INRF and the platform implemented for 
INRF data management based on MOMIS and OpenCli-
nica is a solid foundation both for the secure users access 
to individual’s data and for the clinical management of 
patients. This structure fosters the definition of epidemi-
ology of FSHD as well as definition of its natural history, 
two elements that are crucial for the design of therapeu-
tic interventions.
A mid-term goal of the INRF is the identification of 
factors, including comorbidities or lifestyle habits that 
might influence the disease onset and progression. These 












































Fig. 3 The INRF in the scheme of the world. Pie chart showing the percentage value of FSHD subjects present in each FSHD registry worldwide 
over the total number of patients accrued by all registries. *Data updated to august 2021
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on the analysis of anamnestic records of a vast number of 
subjects and pedigrees. Moreover, the collection of pre-
cisely phenotyped participants might permit their strati-
fication on the basis of standardized criteria, providing 
the framework for further studies that might serve clini-
cal practice and basic research in a rare, understudied 
disease.
The FSHD registry is an evolving tool: this is one of its 
most important features in order to allow longitudinal 
studies and increasing amount of data elaboration, but it 
represents a double edged sword as the registry requires 
to be constantly updated with follow-up information of 
patients to fully exploit its function, otherwise it is in 
danger for becoming a statical survey of a fixed cohort, 
which is not our purpose. It would be of essential help to 
look for an implementation in our database which could 
facilitate the fill in of individual clinical records both for 
clinicians and patients themselves.
In the future, Patient Engagement and Mobile data cap-
ture solutions can be integrated into the existing data-
base to empower patients through self-assessment of 
health indicators. Wearable and clinical devices can be 
used to automatically collect physiological data. Inno-
vative communication strategies will also improve the 
patient’s engagement and Patient Reported Outcomes 
data (ePRO) can be collected in real time employing the 
patient’s smartphones and mobile devices.
To this purpose, it would be of essential help in the 
future to look for an implementation in our database 
which could facilitate the fill in of subject’s clinical 
records both for clinicians and patients themselves.
Our experience with the INRF shows the possibility of 
the systematic collection of clinical data for rare genetic 
diseases on a national scale and its value is providing 
informative observational data that can support clini-
cians, researchers and the health system in acquiring pre-
cise information on rare disorders. We are confident that 
our experience with the integrated management of FSHD 
patients would be taken as an example and applied to 
other complex diseases in which the genotype/phenotype 
correlation is far to be resolved.
Conclusion
The future of medicine lies in personalized treatments. 
In the case of rare genetic diseases, the integration of 
data from genomic analyses, standardized clinical evalu-
ation, collection of environmental and lifestyle data, is 
a precondition to implement person-centered care. The 
systematic collection of clinical data for rare genetic dis-
eases on a National scale is the tool providing informative 
observational data that can support this process.
We propose our experience with the integrated man-
agement of data in a rare disease such as FSHD as a white 
label that could be applied to other complex diseases in 
which the genotype/phenotype correlation is far to be 
resolved.
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